Simple DNA/RNA Probes for Protein Targets

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$194,084.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI075739-01A1
Agency Tracking Number:
AI075739
Solicitation Year:
2008
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2007-2
Small Business Information
ORTHOSYSTEMS, INC.
2-212 CTR FOR SCI AND TECH, 111 COLLEGE PL, SYRACUSE, NY, 13244
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
138843722
Principal Investigator:
() -
Business Contact:
(315) 633-2423
pborer@twcny.rr.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): We describe an integrated approach for rapid discovery of small, structurally defined nucleic acid probe sequences that bind with high affinity and selectivity to a target of interest. Such targets are proteins, bio- terror agents, pathogenic organisms and viruses. The probes will be engineered into proprietary AlloSwitchTM indicators that respond rapidly to the presence of the target, giving rise to a fluorescent or luminescent signal. In this phase I project w e propose to rapidly screen and isolate high-affinity combining probes (c-probes). We will use high throughput methods to isolate at least the known probe sequences specific for alpha-thrombin and platelet derived growth factor (PDGF) from a defined librar y containing billions of DNA sequences. Alternative c-probes for thrombin and PDGF will be sought in libraries that have a predefined secondary structure. In phase II, the approach will be expanded to include a wider variety of structural motifs an d new targets. The targets for discovery of probes and creation of AlloSwitches will include proteins involved in clotting and thrombosis, and growth factors involved in wound healing, angiogenesis, and proliferative diseases. AlloSwitch based assays will assist in the discovery of small molecules that can be used for therapies to regulate the interactions of these proteins in blood. This stands in contrast to therapies based on aptamers or antibodies, which are difficult to protect from hydrolysis by enzym es in plasma. Establishing a highly efficient and rapid screening approach for short DNA/RNA probe discovery will accelerate the commercialization of our biosensor technology in other fields.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government